Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Clin Microbiol Infect ; 30(1): 114-121, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37827383

RESUMEN

OBJECTIVES: Early diagnosis is important in controlling Helicobacter pylori-induced gastritis and progression to gastric malignancy. Serological testing is an efficient non-invasive diagnostic method, but currently does not allow differentiation between active and past infections. To fill this diagnostic gap we investigated the diagnostic value of a panel of ten H. pylori-specific antibodies in individuals with different H. pylori infection status within a German population. METHODS: We used the recomLine Helicobacter IgG 2.0 immunoblotting assay to analyse ten H. pylori-specific antibodies in serum samples collected from 1108 volunteers. From these, 788 samples were used to build exposure and infection status models and 320 samples for model validation. H. pylori infection status was verified by histological examination. We applied logistic regression to select antibodies correlated to infection status and developed, with independent validation, discriminating models and risk scores. Receiving operating characteristic analysis was performed to assess the accuracy of the discriminating models. RESULTS: Antibody reactivity against cytotoxin-associated gene A (CagA), H. pylori chaperone (GroEL), and hook-associated protein 2 homologue (FliD) was independently associated with the risk of H. pylori exposure with ORs and 95% CIs of 99.24 (46.50-211.80), 46.17 (17.45-122.17), and 22.16 (8.46-55.04), respectively. A risk score comprising these three selected antibodies differentiated currently H. pylori infected or eradicated participants from negatives with an area under the curve of 0.976 (95% CI: 0.965-0.987) (Model 1). Seropositivity for vacuolating cytotoxin A (VacA), GroEL, FliD, H. pylori adhesin A (HpaA), and γ-glutamyl transpeptidase (gGT) was associated with a current infection with an area under the curve of 0.870 (95% CI: 0.837-0.903), which may help discriminate currently infected patients from eradicated ones (Model 2). DISCUSSION: The recomLine assay is sensitive and specific in determining H. pylori infection and eradication status and thus represents a valuable tool in the management of H. pylori infection.


Asunto(s)
Gastritis , Infecciones por Helicobacter , Helicobacter pylori , Humanos , Antígenos Bacterianos , Proteínas Bacterianas/genética , Helicobacter pylori/genética , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/microbiología , Gastritis/microbiología , Anticuerpos Antibacterianos , Citotoxinas
2.
Atherosclerosis ; 166(1): 171-6, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12482564

RESUMEN

AIMS: Since infection of endothelial or smooth muscle cells with Chlamydia pneumoniae increased expression of tissue factor and plasminogen activator inhibitor I (PAI-1), C. pneumoniae might be involved in triggering acute thrombotic events in patients with coronary artery disease. Therefore, we explored a potential relationship between IgG-seropositivity to C. pneumoniae and early thrombotic events after coronary stent placement. METHODS AND RESULTS: In a prospective randomized placebo-controlled study 1010 patients with successful coronary stent placement received roxithromycin or placebo for 4 weeks after coronary stent placement, which showed no effect of roxithromycin on early thrombotic events, as expected. Venous blood samples were collected from patients immediately before treatment. Plasma was analyzed for C. pneumoniae-specific IgG antibody levels by microimmuno-fluorescence. Thrombotic events were defined as death, non-fatal myocardial infarction, or urgent target vessel reintervention within 30 days after stent placement. We found no significant difference concerning the frequency of early thrombotic events in patients positive or negative for C. pneumoniae-specific antibodies. If patients were stratified according to their antibody levels, again no significant difference in the frequency of thrombotic events was observed. CONCLUSION: Our findings do not suggest a role of C. pneumoniae in the development of early complications after stent placement.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Chlamydophila/complicaciones , Chlamydophila pneumoniae , Enfermedad Coronaria/terapia , Trombosis Coronaria/prevención & control , Roxitromicina/uso terapéutico , Anciano , Angioplastia de Balón , Anticuerpos Antibacterianos/sangre , Infecciones por Chlamydophila/tratamiento farmacológico , Chlamydophila pneumoniae/inmunología , Enfermedad Coronaria/diagnóstico por imagen , Trombosis Coronaria/etiología , Método Doble Ciego , Femenino , Humanos , Inmunoglobulina G/sangre , Modelos Logísticos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Radiografía , Stents , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...